Skip to main content
. Author manuscript; available in PMC: 2018 Jul 1.
Published in final edited form as: Mol Cancer Res. 2017 Feb 27;15(7):905–914. doi: 10.1158/1541-7786.MCR-16-0369

Figure 3. USP18 regulates endogenous KRAS protein stability.

Figure 3

(A) Endogenous KRAS protein stability decreased with USP18 knockdown. ED1 murine lung cancer cells stably expressing shRNA against USP18 were treated with cycloheximide (CHX) for 15 hours and results were compared to vector-transfected (control) cells. KRAS expression was quantified relative to actin expression at indicated times and normalized to the 0 hour time point (before CHX treatment). Murine USP18 protein expression was detected with a mouse-specific USP18 antibody. (B) Endogenous KRAS protein was stabilized by gain of USP18 expression. HOP62 lung cancer cells transiently overexpressing human GFP-tagged USP18 were treated with CHX for 12 hours and results were compared to vector transfected (control) cells. KRAS protein was quantified relative to actin expression at indicated times and normalized to the 0 hour time point (before CHX treatment). Human USP18 protein expression was detected using a human-specific USP18 antibody.